BCG VACCINE , JNJ-63723283, JNJ-17000139, JNJ-63723283
17000139BLC3002
Phase 3 small_molecule active
Quick answer
BCG VACCINE , JNJ-63723283, JNJ-17000139, JNJ-63723283 for High-Risk Non-muscle-invasive Bladder Cancer is a Phase 3 program (small_molecule) at Janssen-Cilag International N.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Janssen-Cilag International N.V.
- Indication
- High-Risk Non-muscle-invasive Bladder Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active